Quantcast

Latest Humanized antibody Stories

2011-02-08 06:00:00

INCLINE VILLAGE, Nev., Feb. 8, 2011 - PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 13th Annual BIO CEO & Investor Conference on Monday, February 14, 2011, at 11:30 a.m. ET in New York City. This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcasts of the presentation,...

2011-02-08 01:00:00

BRUSSELS and INCLINE VILLAGE, Nev., Feb. 8, 2011 /PRNewswire/ -- UCB SA (Euronext Brussels: UCB), on behalf of its affiliate UCB Pharma S.A. (UCB), and PDL BioPharma, Inc. (Nasdaq: PDLI) (PDL) today jointly announced that the companies have entered into a definitive settlement agreement that resolves all legal disputes between them, including those relating to UCB's pegylated humanized antibody fragment, Cimzia (certolizumab pegol), and PDL's patents known as the Queen et al. patents....

2011-01-05 06:00:00

INCLINE VILLAGE, Nev., Jan. 5, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the company's president and chief executive officer, is scheduled to present at the 29th Annual JP Morgan Healthcare Conference in San Francisco at 7:30 a.m. Pacific time. This presentation will be available to interested parties through a live and archived audio webcast. To access the live and subsequently archived webcast of the presentation, go to the...

2011-01-04 07:00:00

ROCHESTER, N.Y., Jan. 4, 2011 /PRNewswire/ -- Vaccinex, Inc. announced today that it has received clearance from FDA and will initiate a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of therapeutic antibody candidate VX15/2503 in cancer patients with advanced solid tumors. (Logo: http://photos.prnewswire.com/prnh/20101101/NY92716LOGO) VX15/2503 is a novel humanized antibody that blocks the activity of semaphorin 4D (SEMA4D). It is the...

2010-12-07 04:00:00

BURLINGAME, Calif., Dec. 7, 2010 /PRNewswire/ -- Apexigen, Inc. announced today that it has entered into a collaboration and worldwide license agreement with Centocor Research & Development, Inc. and its affiliates to utilize Apexigen's proprietary therapeutic antibody technologies to discover and develop monoclonal antibody drugs. Apexigen will generate and screen antibodies to several targets specified by Centocor R&D, which will be responsible for development and...

2010-10-05 15:09:33

New method will simplify study and treatment of diseases Therapeutic antibodies can be an efficient alternative when common drugs do not work anymore. However, antibodies obtained from blood of animals such as mice could not be used: The human immune system recognizes them as foreign and rejects them. In an international cooperation, scientists from the Helmholtz Centre for Infection Research (HZI) in Braunschweig, Germany have now succeeded in developing a promising approach to solve this...

2010-10-04 06:00:00

INCLINE VILLAGE, Nev., Oct. 4 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that it has paid the October 1, 2010 special dividend payment of $0.50 per share to all stockholders owning shares of PDL as of September 15, 2010, the record date. As previously announced, the conversion rate for the Company's 2.00% Convertible Senior Notes due February 15, 2012 was adjusted to 140.571 shares of common stock per $1,000 principal amount or $7.11 per share. The...

2010-09-08 06:00:00

INCLINE VILLAGE, Nev., Sept. 8 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today announced that John P. McLaughlin, the Company's president and chief executive officer, will present at the following upcoming conferences. Rodman & Renshaw Annual Global Investment Conference Monday, September 13, 2010 4:30 p.m. Eastern time New York City Morgan Stanley Global Healthcare Unplugged Conference Tuesday, September 14, 2010 3:55 p.m. Eastern time...

2010-09-02 04:35:01

Tokyo, Sept 2, 2010 - (JCN Newswire) - Eisai Co., Ltd. announced today the start of the first patient enrolled clinical study with BAN2401, a novel monoclonal antibody that is being developed as a potential next-generation therapeutic treatment for Alzheimer's disease. BAN2401 is the first monoclonal antibody to selectively bind, neutralize and eliminate soluble protofibrils, the toxic amyloid-beta aggregates thought to cause Alzheimer's disease. With this new treatment approach, it is...

2010-08-12 14:50:00

BURLINGAME, Calif., Aug. 12 /PRNewswire/ -- Epitomics, Inc. today announced that it has spun-out to its shareholders a new biotechnology company called Apexigen, Inc., which will focus on the development and commercialization of humanized monoclonal antibodies for treatment of cancer and immuno-disorders. Apexigen was formed with exclusive rights to develop and commercialize therapeutic monoclonal antibodies derived from Epitomics RabMAb® (Rabbit Monoclonal Antibody)...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related